Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-ICH: Aspirin vs Placebo for Secondary Prevention in Intracerebral Haemorrhage
NCT07243704Phase 3
Key facts
- Status
- Recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Countries
- 1
- Sponsor
- Christian Medical College, Vellore
- Modality
- Orthosteric Ligands
- Drugs
- aspirin
- Conditions
- intracerebral hemorrhage (ICH)
01
Overview
Phase 3, randomised, triple-blind trial in intracerebral hemorrhage (ICH) comparing Aspirin 75 mg OD with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 3 years. Started Feb 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedTriple-blind
Aspirin 75 mg OD
Oral daily Aspirin 75 mg OD in addition to standard care.
Placebo
Placebo tablet of similar shape, size, and colour daily in addition to standard care.
03
Who it enrols
Adults with first-ever non-traumatic intracerebral hemorrhage presenting 24 hours to 3 months after symptom onset, with a Glasgow Coma Score > 5, and not on recent antiplatelet or anticoagulant therapy.
04
Endpoints
Primary
Major Adverse Cardiovascular Events
Secondary
Major bleeding
Medication adherence
modified Rankin Scale
Beyond the preview
Go deeper on NCT07243704.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243704.